Citigroup Initiates Coverage On Neurocrine Biosciences with Neutral Rating, Announces Price Target of $127
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang has initiated coverage on Neurocrine Biosciences (NBIX) with a Neutral rating and set a price target of $127.

December 13, 2023 | 9:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Citigroup has initiated coverage on Neurocrine Biosciences with a Neutral rating and a price target of $127.
The initiation of coverage by Citigroup with a Neutral rating suggests that the analyst sees the stock performing in line with the market or sector. The price target of $127 provides a reference point for investors but does not imply significant upside or downside, hence the neutral score. The relevance is high as the news is directly about NBIX. The importance is significant as analyst ratings can influence investor perception and stock price, but it is not at the highest level as the rating is neutral rather than positive or negative. The confidence level is high due to the straightforward nature of the analyst's coverage initiation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100